Three shares indicate that the future fell by more than 11% in Intel.

The US shares have fallen by 0.29% on futures up to the time of the release, the blue-based index, 0.36% on futures of the 500 index, and 0.82% on futures of the 100 NASDAQ index, which is dominated by the science and technology unit. The popular stock market has fallen by 0.08% on the DAX index in Germany, and 1.66% on the CAC 40 index in France, and 1.05% on the 100 index in the UK.

[Financial News] The European Central Bank’s Board of Governors, Muller: It is still too early to discuss interest-reductions, according to the European Central Bank’s Board of Governors, that it is too early to discuss interest-reductions. US Treasury Secretary Ellen: America’s strong GDP growth means higher productivity rather than inflation, and US Treasury Secretary Yelen says on Thursday that America’s unexpected strong economic growth in the fourth quarter is a “good thing” indicating that productivity gains and spending are healthy without rising inflationary pressures.

In response to the US Department of Commerce’s report of 3.3% growth in US gross domestic product (GDP) in the fourth quarter, Ellen said that the report included a core inflation rate of 2%, “which is the Fed’s target,” while the overall inflation rate was low. Saifu will lay off about 700 people on Friday, and the US science and technology industry will send news of another round of layoffs.

Pfizer announced that on January 26, the new oral migraine drug, the Remigic Blast, was approved in China, and Pfizer announced that the new generation of special migraine treatment drugs, the RamiQian Brethren Brethren, had been approved by the National Drug Supervisory Authority (NMPA) of China for acute treatment of adults with or without a priori headaches. According to Pfizer, this is a CGRP-related gene-resistance antigenetic agent that uses the technique of oral cretinoids, effectively disrupts critical pathways associated with migraines, rapidly and continuously mitigates the effects of headaches and associated symptoms, is easily administered, and is resistant to cardiovascular disease.

Q4 performance was disappointing, with Levis joining the downswing: it was proposed to cut at least 10% of the staff, Leavis, a retailer in clothing, whose stock price fell by 2% on Thursday’s post-county deal, following the company’s announcement of its fourth quarter performance and the launch of a restructuring plan that would cut 10-15% globally. The company also offered a sales and profit outlook for 2024, which fell short of what was expected on Wall Street.

The Intel Q1 guide is far less than expected when Intel announced its performance in the fourth quarter of 2023. Data show that the company’s Q4 battalion received $15.4 billion, an increase of 10% compared to the market’s expected $15.2 billion; the adjusted share of proceeds of $0.54 per share is better than the market’s forecast of $0.44.